Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dehydration promotes intracellular lipid synthesis and accumulation.

Nature communications·2026
Same author

Reversal of advanced diabetic kidney disease in mice treated with a monoclonal anti-VEGFR1 antibody.

Kidney international·2026
Same author

A novel mouse model for cardiovascular-kidney-metabolic syndrome: Bridging metabolic, renal and cardiac dysfunction.

Molecular metabolism·2026
Same author

The Role of the Epidermal Growth Factor Receptor in Kidney Tubulointerstitial Fibrosis.

Seminars in nephrology·2026
Same author

Discoidin Domain Receptor 1 Translocation to the Mitochondria Promotes Oxidative Stress and Apoptosis in Acute Kidney Injury.

Journal of the American Society of Nephrology : JASN·2026
Same author

K<sub>ir</sub>5.1-modulated potassium flux stimulates an anabolic kidney phenotype.

iScience·2025

Related Experiment Video

Updated: Jul 13, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

Update on cyclooxygenase-2 inhibitors.

Raymond C Harris1, Matthew D Breyer

  • 1Division of Nephrology, S3322 MCN, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. ray.harris@vanderbilt.edu

Clinical Journal of the American Society of Nephrology : CJASN
|August 21, 2007
PubMed
Summary

Cyclooxygenase-2 (COX-2) inhibitors, designed to reduce side effects of NSAIDs, can still cause kidney and cardiovascular issues. This review details the renal and cardiovascular risks associated with COX-2 selective inhibitors.

More Related Videos

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Related Experiment Videos

Last Updated: Jul 13, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Area of Science:

  • Pharmacology
  • Nephrology
  • Cardiology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation but have significant side effects.
  • Cyclooxygenase-2 (COX-2) selective inhibitors were developed to mitigate gastrointestinal, renal, and cardiovascular risks associated with non-selective NSAIDs.
  • COX-2 plays a crucial role in kidney function, including renin release, sodium balance, and renal blood flow regulation.

Purpose of the Study:

  • To review the current understanding of renal and cardiovascular side effects linked to COX-2 selective inhibitors.
  • To highlight the implications of COX-2 inhibition in the context of kidney function and cardiovascular health.

Main Methods:

  • Literature review of studies investigating COX-2 inhibitors and their side effects.
  • Analysis of the physiological roles of COX-2 in renal and cardiovascular systems.
  • Synthesis of current knowledge on adverse events attributed to COX-2 selective agents.

Main Results:

  • COX-2 is constitutively expressed in the kidney and its activity is sensitive to intravascular volume status.
  • COX-2 metabolites are involved in regulating key renal functions, including blood pressure and electrolyte balance.
  • Evidence suggests that COX-2 selective inhibitors are associated with specific renal and cardiovascular adverse events.

Conclusions:

  • Despite their intended benefits, COX-2 selective inhibitors carry risks for renal and cardiovascular systems.
  • Understanding the role of COX-2 in kidney physiology is critical for evaluating the safety of these drugs.
  • Further research is needed to fully elucidate and manage the cardiovascular and renal side effects of COX-2 inhibitors.